IBEX LTD (IBEX) Stock Fundamental Analysis

NASDAQ:IBEX • BMG4690M1010

29.55 USD
0 (0%)
At close: Feb 20, 2026
29.55 USD
0 (0%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Taking everything into account, IBEX scores 7 out of 10 in our fundamental rating. IBEX was compared to 87 industry peers in the IT Services industry. IBEX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IBEX is growing strongly while it also seems undervalued. This is an interesting combination These ratings would make IBEX suitable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • IBEX had positive earnings in the past year.
  • In the past year IBEX had a positive cash flow from operations.
  • IBEX had positive earnings in each of the past 5 years.
  • IBEX had a positive operating cash flow in each of the past 5 years.
IBEX Yearly Net Income VS EBIT VS OCF VS FCFIBEX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

1.2 Ratios

  • With an excellent Return On Assets value of 14.58%, IBEX belongs to the best of the industry, outperforming 93.10% of the companies in the same industry.
  • IBEX has a Return On Equity of 28.81%. This is amongst the best in the industry. IBEX outperforms 89.66% of its industry peers.
  • IBEX has a better Return On Invested Capital (21.63%) than 95.40% of its industry peers.
Industry RankSector Rank
ROA 14.58%
ROE 28.81%
ROIC 21.63%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBEX Yearly ROA, ROE, ROICIBEX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100

1.3 Margins

  • The Profit Margin of IBEX (7.14%) is better than 73.56% of its industry peers.
  • IBEX's Profit Margin has improved in the last couple of years.
  • Looking at the Operating Margin, with a value of 9.18%, IBEX is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
  • In the last couple of years the Operating Margin of IBEX has grown nicely.
  • With a Gross Margin value of 30.62%, IBEX perfoms like the industry average, outperforming 42.53% of the companies in the same industry.
  • In the last couple of years the Gross Margin of IBEX has remained more or less at the same level.
Industry RankSector Rank
OM 9.18%
PM (TTM) 7.14%
GM 30.62%
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
IBEX Yearly Profit, Operating, Gross MarginsIBEX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • IBEX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • IBEX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IBEX Yearly Shares OutstandingIBEX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
IBEX Yearly Total Debt VS Total AssetsIBEX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 4.83 indicates that IBEX is not in any danger for bankruptcy at the moment.
  • IBEX has a better Altman-Z score (4.83) than 80.46% of its industry peers.
  • IBEX has a debt to FCF ratio of 0.05. This is a very positive value and a sign of high solvency as it would only need 0.05 years to pay back of all of its debts.
  • The Debt to FCF ratio of IBEX (0.05) is better than 91.95% of its industry peers.
  • IBEX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • With an excellent Debt to Equity ratio value of 0.01, IBEX belongs to the best of the industry, outperforming 83.91% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.05
Altman-Z 4.83
ROIC/WACC2.2
WACC9.82%
IBEX Yearly LT Debt VS Equity VS FCFIBEX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 1.82 indicates that IBEX should not have too much problems paying its short term obligations.
  • IBEX has a Current ratio (1.82) which is comparable to the rest of the industry.
  • IBEX has a Quick Ratio of 1.82. This is a normal value and indicates that IBEX is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.82, IBEX perfoms like the industry average, outperforming 55.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.82
IBEX Yearly Current Assets VS Current LiabilitesIBEX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 44.77% over the past year.
  • Measured over the past years, IBEX shows a very strong growth in Earnings Per Share. The EPS has been growing by 41.04% on average per year.
  • IBEX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.77%.
  • The Revenue has been growing slightly by 6.62% on average over the past years.
EPS 1Y (TTM)44.77%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%47.46%
Revenue 1Y (TTM)9.77%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.73%

3.2 Future

  • The Earnings Per Share is expected to grow by 13.72% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 9.19% on average over the next years. This is quite good.
EPS Next Y22.95%
EPS Next 2Y13.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year12.81%
Revenue Next 2Y9.19%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBEX Yearly Revenue VS EstimatesIBEX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
IBEX Yearly EPS VS EstimatesIBEX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 8.54, which indicates a very decent valuation of IBEX.
  • Compared to the rest of the industry, the Price/Earnings ratio of IBEX indicates a rather cheap valuation: IBEX is cheaper than 88.51% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of IBEX to the average of the S&P500 Index (26.99), we can say IBEX is valued rather cheaply.
  • A Price/Forward Earnings ratio of 8.16 indicates a reasonable valuation of IBEX.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of IBEX indicates a rather cheap valuation: IBEX is cheaper than 90.80% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.06. IBEX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 8.54
Fwd PE 8.16
IBEX Price Earnings VS Forward Price EarningsIBEX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 90.80% of the companies in the same industry are more expensive than IBEX, based on the Enterprise Value to EBITDA ratio.
  • IBEX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. IBEX is cheaper than 71.26% of the companies in the same industry.
Industry RankSector Rank
P/FCF 12.7
EV/EBITDA 5.32
IBEX Per share dataIBEX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • IBEX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • IBEX has a very decent profitability rating, which may justify a higher PE ratio.
  • IBEX's earnings are expected to grow with 13.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.37
PEG (5Y)0.21
EPS Next 2Y13.72%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • IBEX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IBEX LTD

NASDAQ:IBEX (2/20/2026, 8:00:01 PM)

After market: 29.55 0 (0%)

29.55

0 (0%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)02-05
Earnings (Next)05-06
Inst Owners94.08%
Inst Owner Change-0.03%
Ins Owners2.8%
Ins Owner Change14.36%
Market Cap396.27M
Revenue(TTM)558.27M
Net Income(TTM)41.38M
Analysts45.71
Price Target41.82 (41.52%)
Short Float %0.8%
Short Ratio0.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.95%
Min EPS beat(2)20.05%
Max EPS beat(2)21.85%
EPS beat(4)4
Avg EPS beat(4)16.83%
Min EPS beat(4)10.89%
Max EPS beat(4)21.85%
EPS beat(8)7
Avg EPS beat(8)12.58%
EPS beat(12)10
Avg EPS beat(12)14.59%
EPS beat(16)12
Avg EPS beat(16)13.3%
Revenue beat(2)2
Avg Revenue beat(2)5.51%
Min Revenue beat(2)2.5%
Max Revenue beat(2)8.52%
Revenue beat(4)4
Avg Revenue beat(4)4.65%
Min Revenue beat(4)2.45%
Max Revenue beat(4)8.52%
Revenue beat(8)5
Avg Revenue beat(8)1.79%
Revenue beat(12)5
Avg Revenue beat(12)-0.35%
Revenue beat(16)7
Avg Revenue beat(16)-0.06%
PT rev (1m)0%
PT rev (3m)6.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.48%
EPS NY rev (1m)0%
EPS NY rev (3m)5.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.82%
Valuation
Industry RankSector Rank
PE 8.54
Fwd PE 8.16
P/S 0.68
P/FCF 12.7
P/OCF 7.4
P/B 2.76
P/tB 3.01
EV/EBITDA 5.32
EPS(TTM)3.46
EY11.71%
EPS(NY)3.62
Fwd EY12.25%
FCF(TTM)2.33
FCFY7.87%
OCF(TTM)4
OCFY13.52%
SpS43.23
BVpS10.71
TBVpS9.83
PEG (NY)0.37
PEG (5Y)0.21
Graham Number28.88
Profitability
Industry RankSector Rank
ROA 14.58%
ROE 28.81%
ROCE 26.64%
ROIC 21.63%
ROICexc 24.4%
ROICexgc 26.15%
OM 9.18%
PM (TTM) 7.14%
GM 30.62%
FCFM 5.38%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
F-Score8
Asset Turnover2.04
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.05
Debt/EBITDA 0.01
Cap/Depr 129.83%
Cap/Sales 3.86%
Interest Coverage 31.53
Cash Conversion 76.01%
Profit Quality 75.39%
Current Ratio 1.82
Quick Ratio 1.82
Altman-Z 4.83
F-Score8
WACC9.82%
ROIC/WACC2.2
Cap/Depr(3y)83.97%
Cap/Depr(5y)108.52%
Cap/Sales(3y)2.89%
Cap/Sales(5y)3.72%
Profit Quality(3y)75.63%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.77%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%47.46%
EPS Next Y22.95%
EPS Next 2Y13.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.77%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.73%
Revenue Next Year12.81%
Revenue Next 2Y9.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.48%
EBIT growth 3Y33.16%
EBIT growth 5Y20.06%
EBIT Next Year68.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.26%
FCF growth 3Y24.66%
FCF growth 5Y-10.09%
OCF growth 1Y19.11%
OCF growth 3Y4.51%
OCF growth 5Y-2.46%

IBEX LTD / IBEX FAQ

Can you provide the ChartMill fundamental rating for IBEX LTD?

ChartMill assigns a fundamental rating of 7 / 10 to IBEX.


What is the valuation status for IBEX stock?

ChartMill assigns a valuation rating of 8 / 10 to IBEX LTD (IBEX). This can be considered as Undervalued.


What is the profitability of IBEX stock?

IBEX LTD (IBEX) has a profitability rating of 7 / 10.


What is the valuation of IBEX LTD based on its PE and PB ratios?

The Price/Earnings (PE) ratio for IBEX LTD (IBEX) is 8.54 and the Price/Book (PB) ratio is 2.76.


Is the dividend of IBEX LTD sustainable?

The dividend rating of IBEX LTD (IBEX) is 0 / 10 and the dividend payout ratio is 0%.